Company intelligence / Profile preview
Interplay Bio
Ypsilanti, Michigan, United Statesinterplay.bio ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has identified two molecules with high potential for pancreatic ductal adenocarcinoma (PDAC) and has a pipeline of 30 new small molecule-protein interactions. They are seeking partnerships for further development and commercialization.
- Therapeutic areas
- OncologyMetabolic DisordersNeurology
- Modalities
- Small moleculesTargeted Protein Degraders (TPDs)Molecular Glue Degraders
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Seeking pharmaceutical partnerships for development and commercialization
Beyond the preview
Go deeper on Interplay Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interplay Bio.